Tourmaline Bio (TRML) Revenue & Revenue Breakdown
Tourmaline Bio Revenue Highlights
00
Tourmaline Bio Revenue by Period
Tourmaline Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Tourmaline Bio generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Tourmaline Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $40.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.28M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Tourmaline Bio generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Tourmaline Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| WVE | Wave Life Sciences | $108.30M | $7.61M |
| AMLX | Amylyx Pharmaceuticals | $87.37M | - |
| IMTX | Immatics | $54.00M | $30.45M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $45.87M |
| RLAY | Relay Therapeutics | $10.01M | - |
| DNTH | Dianthus Therapeutics | $6.24M | $193.00K |
| PGEN | Precigen | $3.92M | $856.00K |
| ELVN | Enliven Therapeutics | - | - |
| TRML | Tourmaline Bio | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |